GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$48.13
0.01 (0.02%)
▲
5d:
-5.39%
30d:
-4.31%
90d:
-8.95%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GSK shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GSK shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.83
Based on 4.0% avg growth
INTRINSIC VALUE TODAY
$39.01
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $48.13, which is considered oversold relative to its 30-day fair value range of $49.51 to $52.11. The stock's valuation (Forward PE: 9.7) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $47.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.58 (+21.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $47.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK scores 19/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $58.58 (+21.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$49.51 -
$52.11
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (19/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.7% below Wall St target ($58.58)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$49.51 -
$52.11
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$47.85
Resistance Level
$51.52
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.67
Wall Street Target
$58.58
(+21.7%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
-69.5%
Profit Margin
14.5%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
9.7 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$47.02
(-2%)
2-Year Target
$45.94
(-5%)
3-Year Target
$44.88
(-7%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$48.28
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 3.9%)
$112.63
(+134%)
Base:
(SPY PE: 9.7, Growth: 3.9%)
$53.99
(+12%)
Bear:
(PE: 8.2, Growth: 3.9%)
$45.89
(-5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 15.08 | Current EPS (TTM): $3.19
Bull Case
$82.59
(+72%)
Analyst growth 56.0%, PE expands to 16.6
Base Case
$75.08
(+56%)
Market implied 56.0%, PE stable at 15.1
Bear Case
$32.72
(-32%)
Severe decline -20.0%, PE contracts to 12.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.7 to 10.4
Stabilization Target:
$51.77
(+7.6%)
PE Expansion Potential:
+7.6%
Share & Embed Analysis
Last updated: September 12, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1316 | 47 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 44 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 53 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$237 | 47 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$390 | 43 HOLD |
